Molecule
Veligrotug is a prescription medicine indicated for the treatment of thyroid eye disease regardless of thyroid eye disease activity or duration. It is available as injection for intravenous use. MedsAcross supplies Veligrotug for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
From the regulator-approved product information. Each section names its source.
LUMVOA is indicated for the treatment of thyroid eye disease regardless of thyroid eye disease activity or duration. LUMVOA is an insulin-like growth factor-1 receptor inhibitor indicated for the treatment of thyroid eye disease regardless of thyroid eye disease activity or duration.
Source: US FDA prescribing information
Veligrotug-vvze's mechanism of action in patients with thyroid eye disease has not been fully characterized. Veligrotug-vvze is a humanized IgG1 monoclonal antibody that binds to IGF-1R and inhibits IGF-1R signaling by blocking ligand-induced receptor autophosphorylation.
Source: US FDA prescribing information
10 mg/kg every three weeks for a total of 5 infusions. Administer LUMVOA by intravenous infusion over 30 to 45 minutes. See full prescribing information for dose preparation and administration instructions
Source: US FDA prescribing information
None None
Source: US FDA prescribing information
Infusion Reactions: If an infusion reaction occurs, interrupt or slow the rate of infusion and use appropriate medical management. Inflammatory Bowel Disease (IBD): Monitor patients for signs and symptoms of disease, including patients without a history of IBD, discontinue LUMVOA if IBD is suspected. Hyperglycemia: Assess patients for elevated blood glucose and symptoms of hyperglycemia prior to infusion and continue to monitor while on treatment with LUMVOA. Ensure patients with hyperglycemia or preexisting diabetes are under appropriate glycemic control before and while receiving LUMVOA. Continue monitoring after treatment for patients who experience hyperglycemia while on LUMVOA. Hearing Impairment including Hearing Loss: LUMVOA may cause severe hearing impairment including hearing loss, which in some cases may be permanent.
Source: US FDA prescribing information
The following clinically significant adverse reactions are described elsewhere in the labeling: Infusion Reactions Inflammatory Bowel Disease Hyperglycemia Hearing Impairment Most common adverse reactions (incidence of 5% or more) are muscle spasms, headache, hearing impairment, hyperglycemia, fatigue, diarrhea, ear discomfort, infusion-related reaction, nausea, nasopharyngitis, blood creatine phosphokinase increased, dry skin, and hypertension
Source: US FDA prescribing information
Store refrigerated at 2°C to 8°C (36°F to 46°F) in original carton to protect from light. Do not freeze. Do not shake.
Source: US FDA prescribing information
For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
1 presentations of Veligrotug, sorted by availability.
| Medicine | Manufacturer | Register | Availability |
|---|---|---|---|
| Lumvoa 500 mg/10 mL injectionIntravenous Cold chain | Viridian Therapeutics | US FDA | Available on request |
1 brand names across 1 markets.
United States
Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.
| Register | Status | Source |
|---|---|---|
| US FDA | First approved 26 June 2026 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Yes, on request. MedsAcross lists 1 presentations of Veligrotug and sources them for licensed hospitals, importers and physicians against valid import documents.
The catalogue lists 1 brand names for Veligrotug, including Lumvoa.
Yes. The US FDA first approved Veligrotug on 26 June 2026, according to Drugs@FDA.
At least one listed presentation of Veligrotug must be kept cold, so it is shipped in temperature-controlled packaging. Check the storage line on each presentation.
Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.